- Conditions
- Obesity
- Interventions
- CAAT: Appetite Awareness, CRST: Volcravo, Combined CAAT and CRST program
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 7,852
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide Once Weekly, Insulin Glargine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 12
- States / cities
- Escondido, California • Jacksonville, Florida • Orlando, Florida + 9 more
- Conditions
- Prostate Cancer, Hormone Refractory Prostate Cancer
- Interventions
- Satraplatin, Prednisone
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 90 more
- Conditions
- Tobacco Toxicant Exposure
- Interventions
- Deuterated NNN
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
- Interventions
- CLBR001 and SWI019
- Combination Product
- Lead sponsor
- Calibr, a division of Scripps Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 8
- States / cities
- Duarte, California • San Diego, California • Chicago, Illinois + 5 more
- Conditions
- Respiratory Distress Syndrome
- Interventions
- Not listed
- Lead sponsor
- Children's Hospitals and Clinics of Minnesota
- Other
- Eligibility
- 1 Day to 30 Days
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Abdominal Aortic Aneurysm
- Interventions
- Decision aid
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
- Conditions
- Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
- Interventions
- Not listed
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,764 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 86
- States / cities
- Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 76 more
- Conditions
- Hyperlipidemia
- Interventions
- Bococizumab (PF-04950615;RN316), Atorvastatin, Placebo for Bococizumab (PF-04950615;RN316), Placebo for atorvastatin
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 31
- States / cities
- Denver, Colorado • Bridgeport, Connecticut • Lakeland, Florida + 24 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Reyataz + Norvir + Truvada, Reyataz + Epzicom
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 44
- States / cities
- Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
- Conditions
- Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
- Interventions
- SPR001
- Drug
- Lead sponsor
- Spruce Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 9
- States / cities
- Orange, California • San Diego, California • Melbourne, Florida + 6 more
- Conditions
- Renal Impairment
- Interventions
- RO7079901
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
- Conditions
- Optim Lead Insulation Related Adverse Events
- Interventions
- Not listed
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2020
- U.S. locations
- 245
- States / cities
- Alabaster, Alabama • Fort Payne, Alabama • Gadsden, Alabama + 189 more
- Conditions
- Hyperphosphatemia Related to Chronic Kidney Disease
- Interventions
- ferric citrate
- Drug
- Lead sponsor
- Keryx Biopharmaceuticals
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 11 more
- Conditions
- Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
- Interventions
- 2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 60
- States / cities
- Campbell, California • Glendale, California • Huntington Beach, California + 50 more
- Conditions
- Cystic Fibrosis
- Interventions
- AquADEKs-2, control multivitamin
- Drug · Dietary Supplement
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Aurora, Colorado • Orlando, Florida + 12 more
- Conditions
- Colorectal Cancer
- Interventions
- leucovorin calcium, tegafur-uracil
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 75 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 49
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 35 more
- Conditions
- Hypertension
- Interventions
- Darusentan, Guanfacine, Darusentan Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 849 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 719 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
- Conditions
- Type 2 Diabetes
- Interventions
- Continuous Glucose Monitoring (CGM)
- Device
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Metastatic Melanoma
- Interventions
- vemurafenib + HD IL-2
- Drug
- Lead sponsor
- Clinigen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 18 more
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- 0.15% azelastine hydrochloride, Mometasone furoate
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 59
- States / cities
- Oxford, Alabama • Fountain Valley, California • Huntington Beach, California + 50 more
- Conditions
- Peripheral Vascular Disease, Cardiovascular Disease
- Interventions
- Vessel Closure (StarClose™)
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 11
- States / cities
- La Jolla, California • Atlanta, Georgia • Peoria, Illinois + 8 more